-
BMS Press Release is out now
European Medicines Agency Validates Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive…
-
Press Release: High risk of financial vulnerability after diagnosis: The majority of people impacted by lung cancer experience higher costs and reduction in income
High risk of financial vulnerability after diagnosis: The majority of people impacted by lung cancer experience higher costs and reduction in income Financial impact of lung…
-
8th Edition of the LuCE Report – Financial impact of lung cancer: A European perspective
This is an annual initiative led by lung cancer patient organisations, across Europe with the purpose of raising awareness relating to the main challenges faced…
-
8th LuCE Report on Lung Cancer: Launch Event
Join us at our launch of the 8th LuCE report: “Financial impact on lung cancer: A European Perspective”
-
LuCE attending the European Medicines Agency (EMA) in Amsterdam
November 14th – 15th in Amsterdam We are delighted to announce that Lung Cancer Europe (LuCE) is participating in a two-day meeting at the European Medicines Agency…
-
Remembering Marjo Forsblom
We are very sad to share the heartbreaking news that Marjo Forsblom passed away on Sunday October 22nd 2023. Marjo was a beautiful shining light…
-
Highlights of ESMO Congress 2023
LuCE present at the ESMO Congress 2023 October 20th-24th in Madrid, Spain Our president Anne-Marie Baird had an active participation at the ESMO Congress as…
-
Introducing our newest Member: Lungunion Austria
About the Organization Lungunion Austria The Lungunion Austria is a patient organization (NGO and self-aid organization) for people with airway diseases, aligned skin diseases, and…
-
Best Advocacy Initiative: Athena.Women Against Cancer
During our Members Meeting 2023, 11 members presented their advocacy initiatives where they shared their goals, projects and accomplishments. With an overwhelming number of votes,…